Scott B. Ullem is CFO at Edwards Lifesciences Corp (EW). They have made 22 open-market trades across 1 company since 2018, most recently 2026-09-30.
CIK 0001446989
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 22 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| EW | 46,740 | $4.0M |
| ILMN | 11,143 | $2.9M |
| BMS | 34,074 | $2.0M |
| BERY | 4,728 | $320K |
| Total | $9.2M |
Shares reported on the most recent Form 4, priced at the 2026-10-02 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| EW | SELL · 10b5-1 | 2026-04-09 | 2026-04-09 | $80.04 | $1.0M | +0.7% | -2.5% | +18.4% |
| EW | SELL | 2026-03-11 | 2026-03-11 | $84.92 | $1.1M | -3.5% | -8.3% | +3.0% |
| EW | SELL · 10b5-1 | 2025-12-09 | 2025-12-09 | $84.47 | $650K | +2.6% | +1.4% | +1.0% |
| EW | SELL · 10b5-1 | 2025-11-10 | 2025-11-10 | $83.08 | $2.2M | -0.4% | -0.6% | -9.0% |
| EW | SELL · 10b5-1 | 2025-05-09 | 2025-05-09 | $74.40 | $1.7M | +2.3% | +2.6% | +4.7% |
| EW | SELL · 10b5-1 | 2025-03-26 | 2025-03-26 | $70.87 | $1.6M | -2.6% | +7.4% | +7.1% |
| EW | SELL · 10b5-1 | 2025-02-28 | 2025-02-28 | $70.79 | $1.6M | -5.1% | +0.4% | +7.7% |
| EW | SELL · 10b5-1 | 2025-02-13 | 2025-02-13 | $75.76 | $852K | -5.6% | -7.3% | +0.7% |
| EW | SELL · 10b5-1 | 2024-12-09 | 2024-12-09 | $71.68 | $1.6M | +3.8% | +4.1% | -3.8% |
| EW | SELL · 10b5-1 | 2024-06-20 | 2024-06-20 | $87.49 | $949K | +1.8% | -1.8% | -24.6% |
| EW | SELL · 10b5-1 | 2024-05-21 | 2024-05-21 | $90.45 | $1.0M | -3.4% | -2.3% | -24.9% |
| EW | SELL · 10b5-1 | 2024-04-30 | 2024-04-30 | $85.86 | $683K | +3.1% | +4.5% | -24.2% |
| EW | SELL · 10b5-1 | 2024-04-01 | 2024-04-01 | $94.89 | $1.4M | -2.2% | -9.8% | -3.4% |
| EW | SELL · 10b5-1 | 2024-02-29 | 2024-02-29 | $85.59 | $1.2M | +7.7% | +11.7% | +3.1% |
| EW | SELL · 10b5-1 | 2024-02-01 | 2024-02-01 | $78.29 | $1.1M | +7.8% | +8.8% | +5.4% |
| EW | SELL · 10b5-1 | 2023-12-29 | 2023-12-29 | $76.55 | $2.2M | -0.7% | -1.5% | +26.3% |
| EW | SELL · 10b5-1 | 2023-10-31 | 2023-10-31 | $62.66 | $909K | +1.1% | +6.6% | +17.4% |
| EW | SELL · 10b5-1 | 2023-09-29 | 2023-09-29 | $69.54 | $1.0M | +3.3% | -9.4% | +11.4% |
| EW | SELL · 10b5-1 | 2023-08-31 | 2023-08-31 | $77.79 | $1.1M | -5.2% | -10.4% | -12.6% |
| EW | SELL · 10b5-1 | 2023-07-31 | 2023-07-31 | $84.35 | $1.2M | -4.0% | -4.5% | -23.5% |
| EW | SELL · 10b5-1 | 2023-06-30 | 2023-06-30 | $93.27 | $1.4M | -0.6% | -12.3% | -25.3% |
| EW | SELL · 10b5-1 | 2023-05-10 | 2023-05-11 | $88.54 | $14.3M | -4.5% | -3.6% | -12.1% |
| EW | SELL | 2020-10-26 | 2020-10-26 | $78.81 | $5.2M | -1.0% | +7.5% | +9.6% |
| EW | SELL | 2020-10-12 | 2020-10-13 | $83.89 | $3.3M | -4.2% | -4.3% | +6.5% |
| EW | SELL | 2020-09-28 | 2020-09-28 | $78.11 | $5.2M | +4.2% | -6.5% | +15.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.